Publications

Export 24100 results:
Sort by: [ Author  (Asc)] Title Type Year
[A] B C D E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
A
Azhary, R. A., M. T. Khayyal, and S. Saleh, "Effect of fluphenazine on tissue noradrenaline concentrations and its interaction with pargyline.", British journal of pharmacology, vol. 53, issue 4, pp. 593-5, 1975 Apr. Abstract

Fluphenazine caused a small decrease in the noradrenaline (NA) concentrations of the rat brain, possibly by impairing granular amine storage. The drug diminished the rise in brain and heart NA concentrations induced by pargyline, suggesting that it might posses inhibitory properties on neuronal uptake mechanisms and/or NA synthesis. Fluphenazine abolished conditioned avoidance responses in rats, an effect which was maintained after the concomitant administration of pargyline, when NA concentrations remained high. This suggests that the fluphenazine-induced sedation is not mediated via its effect on brain NA content, but is possibly due to the effect of the drug on NA turnover rates in the brain.

Azim, H. A., Y. S. E. D. Abdal-Kader, M. M. Mousa, R. A. Malek, M. K. Abdalmassih, and N. Y. Ibrahim, Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients, , vol. 16, pp. 65 - 69, 2015. Abstract
n/a
Azim, H. A., L. Kassem, I. Treilleux, Q. Wang, M. A. E. Enein, S. E. Anis, and T. Bachelot, Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer, , vol. 9, issue 2: Elsevier, pp. 114 - 123, 2016. Abstract
n/a
Azim, H. A., K. S. Shohdy, D. F. Kaldas, L. Kassem, and H. A. Azim, "Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis", Current Problems in Cancer, vol. 44, issue 6, pp. 100592 - 100592, 2020/12//. Abstract
n/a
Azim, H. A., N. S. Kamal, and R. A.Malek, "Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!", Journal of Thoracic Diseases, vol. 5, issue suppl 1, pp. 27-35, 2013.
Azim, H. A., A. Omar, H. Atef, H. Zawahry, M. K. Shaker, A. H. K. Abdelmaksoud, M. EzzElarab, O. Abdel-Rahman, M. Ismail, L. Kassem, et al., "Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study).", Journal of hepatocellular carcinoma, vol. 5, pp. 109 - 119, 2018///. AbstractWebsite

Background Phase II trials found that tegafur-uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. Our Phase II randomized trial aimed to evaluate efficacy and tolerability of sorafenib plus UFT vs sorafenib in advanced HCC. Methods Patients with advanced HCC, with no prior systemic therapy, were randomized to receive either UFT at 125 mg/m2 twice daily for 4 out of 5 weeks plus sorafenib at 400 mg twice daily (arm 1) or single agent sorafenib at 400 mg twice daily (arm 2). Primary end point was time to progression (TTP). Results Between March 2012 and March 2014, 76 eligible patients - out of 143 preplanned - were randomized. The study was terminated early because of futility. This is the final analysis of the study, after a median follow-up of 10.2 months and death of 86% of randomized patients (n=64). Median TTP was 7.5 months and 8.2 months in arms 1 and 2 respectively (HR: 1.07; 95% CI, 0.52-2.22; P=0.855), while the median overall survival was 8.2 months and 10.5 months respectively (HR: 1.58; 95% CI: 0.90-2.76, P=0.112). Nine patients (25%) in the combination arm discontinued treatment because of toxicity vs eight patients (21.1%) in the sorafenib monotherapy arm (P=0.899). Conclusion In patients with advanced HCC, adding UFT to sorafenib is feasible, but it did not improve efficacy outcome over sorafenib monotherapy.

Azim, A. A. Y., A. S. Hanafy, and E. E. Khalil, "Subcooled Flow Boiling of Water Enhancement by Using Internal Surface Coating", International Journal of Thermal & Environmental Engineering, Jordan, 10 Dec., 2011.
Azim, H. A., A. Omar, H. Atef, H. Zawahry, M. K. Shaker, A. H. K. Abdelmaksoud, M. EzzElarab, O. Abdel-Rahman, M. Ismail, and L. Kassem, Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study), , vol. 5: Dove Press, pp. 109, 2018. Abstract
n/a
Azim, H. A., S. Lasheen, and L. Kassem, Treatment of HER 2‐positive early breast cancer: How to best balance efficacy and toxicity?, , vol. 24, issue 4, pp. 459 - 461, 2018. Abstract
n/a
Azim, S. A. A., H. A. Darwish, M. Z. Rizk, S. A. Ali, and M. O. Kadry, "Amelioration of titanium dioxide nanoparticles-induced liver injuryin mice: Possible role of some antioxidants", Experimental and Toxicologic Pathology, vol. 67 , pp. 305–314, 2015.
Azim, S. A. A., R. M. Hussein, A. A. Badr, and M. R. Rizk, "Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells Against Isoniazid and RifampicinInduced Hepatorenal Toxicity in Rats ", Life Science Journal , vol. 11, issue 12, pp. 1036-1046, 2014.
tarek Azim, "Charginos and Z-gauge boson production at e+ e- supercollider", International conference on modem development in elementary particles physics, pp. 36, 1999.
Azim, H. A., M. K. A. 12 Yasser S Abdal-Kader Mohamed Mahmoud Mousa1, Raafat Abdel Malek1, M. M. Mousa, R. A. Malek, M. K. Abdalmassih, and N. Y. Ibrahim, "Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients", Asian Pacific Journal Cancer Prevention, vol. 16, issue 1, pp. 65-69, 2015. 65-69_7.26_hamdy_a_azim-2.pdf
Azim, H. A., K. S. Shohdy, H. Elghazawy, M. M. Salib, D. Almeldin, and L. Kassem, "Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis", Biomarkers, pp. 1 - 9, 2022/08//. Abstract
n/a
Azim, H. A., L. Santoro, R. G. Bociek, S. Gandini, R. A. Malek, and J. H.A. Azim, "High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis ", Annals of Oncology, vol. 21, issue 5, pp. 1064-1071, 2010.
Azim, H. A., and A. S. Ibrahim, Breast cancer in Egypt, China and Chinese: statistics and beyond, , vol. 6, issue 7: AME Publications, pp. 864, 2014. Abstract
n/a
Azim, H. A., Y. S. Abdal-Kader, M. M. Mousa, R. Abdel-Malek, M. K. Abdalmassih, and N. O. H. A. Y. E. H. I. A. IBRAHIM, "Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients", Asian Pacific Journal of Cancer Prevention, vol. 16, issue 1, pp. 65-69, 2015. 65-69_7.26_hamdy_a_azim.pdf
Azim, H. A., L. Kassem, I. Treilleux, Q. Wang, M. A. E. Enein, S. E. Anis, and T. Bachelot, Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer, , vol. 9, issue 2: Elsevier, pp. 114 - 123, 2016. Abstract
n/a
Azim, H. A., O. Abdel-Rahman, and R. Abdel-Malek, Bilateral Phyllodes Tumor of the Breast; a Case Report of Benign Tumor on One Side and Malignant Tumor on the Contralateral Side, , vol. 13, issue 2: Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical …, pp. 56 - 58, 2017. Abstract
n/a
tarek Azim, "Pair production of Charginos in e + e- annihilation at high energies ", Mod. Phys. Lett., vol. 7, issue 17, pp. 1535, 1992.
tarek Azim, "Production of Z-Boson and vv pair", Journal of the faculty of education, vol. 4, issue 16, pp. 16, 1991.
Azim, H. A., and H. A. Azim Jr, Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions, , vol. 8, issue 2: Future Medicine, pp. 135 - 144, 2012. Abstract
n/a
Azim, [2] A. A. Y., A. S. Hanafy, G. M. Mostafa, and E. E. Khalil, "Enhanced Subcooled Flow Boiling of Water by Using Internal Surface Coating", 9th Annual International Energy Conversion Engineering Conference (AIAA), San Diego, 3 August, 2011.
Azim, E. A. A., S. A. Elkheshen, R. M. Hathout, M. A. Fouly, and N. E. M. Hoffy, "Augmented in vitro and in vivo Profiles of Brimonidine Tartrate Using Gelatinized-Core Liposomes", International Journal of Nanomedicine, vol. 17, pp. 2753–2776, 2022.